The introduction of Retatrutide ZPHC, at a concentration of 120mg, is generating considerable interest within the weight loss community. This novel dual GIP and GLP-1 target medication suggests to deliver significant improvements in weight reduction compared to existing therapies. Preliminary research data have shown marked declines in body mass ,